Key Performance
More- Earnings Score: 66
- Momentum Score: 57
- True Yield: N/A
- Financial Health Score: 37
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Syndax Announces Participation in Upcoming Investor Conferences
Syndax Pharmaceuticals announced that CEO Michael A. Metzger and management team will participate in three major investor conferences in May-June 2026: TD Cowen 7th Annual Oncology Innovation Summit (May 27), Jefferies Global Healthcare Conference (June 4), and Goldman Sachs 47th Annual Global Healthcare Conference (June 8). Live webcasts will be available on the company's website.
05/20/2026, 7:00 AM • GlobeNewswire
Sphera Funds Management Ltd. invested $6.54 million in Syndax Pharmaceuticals by purchasing 374,847 shares in Q4 2025. Syndax has demonstrated strong commercial traction with two approved therapies generating $172.4 million in annual revenue, up significantly from $23.7 million the prior year. The stock has surged over 80% in the past year, reflecting accelerating adoption of its oncology treatments.
03/13/2026, 9:09 AM • The Motley Fool
Syndax Pharmaceuticals and the World Orphan Drug Alliance announced a collaboration to expand access to Revuforj (revumenib), a first-in-class menin inhibitor, through a Managed Access Program in regions including parts of Eurasia, Central and Southeast Europe, Israel, the Middle East, Turkey, Latin America, and Africa where the drug is not yet commercially available.
01/07/2026, 7:00 AM • GlobeNewswire
Syndax Announces Participation at the 8th Annual Evercore Healthcare Conference
Syndax Pharmaceuticals' CEO will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference, discussing the company's innovative cancer therapies and pipeline developments.
12/01/2025, 7:00 AM • GlobeNewswire
The FDA approved Revuforj (revumenib) for treating relapsed or refractory acute myeloid leukemia with NPM1 mutation in adult and pediatric patients, marking the first and only therapy approved for multiple acute leukemia subtypes.
10/24/2025, 1:58 PM • GlobeNewswire
Market report highlights emerging menin inhibitor drugs targeting high-risk acute leukemias, with over 15 drugs in clinical trials and potential market opportunity exceeding $400 million by 2028.
10/10/2025, 4:54 AM • GlobeNewswire
Syndax Pharmaceuticals will report its Q2 2025 financial results and host a conference call on August 4, 2025, providing an update on its innovative cancer therapies and ongoing clinical trials.
07/28/2025, 7:00 AM • GlobeNewswire
